Skip to main content


July 30-August 1 | Chicago, IL | Booth #1742


See PATHFAST® hs-cTn-II, the first and only high-sensitivity cardiac troponin (hs-cTn) assay cleared for point-of-care (POC) use by the FDA.


Helping save lives through the early detection of life-threatening diseases


Live PATHFAST Analyzer demonstration

See PATHFAST in action.


ADLM Industry Workshop

Cardiac troponin I POC testing in the emergency department

Presented by Dr Robert Christenson

Wed, July 31, 3:30 pm CT Exhibit Hall #1


Live OC-Auto FIT® demonstration

Exceed your colorectal cancer screening goals with OC-Auto FIT.

The wait is over

PATHFAST hs-cTnl-II at the point of care

Now FDA-cleared

hs-cTn is the preferred assay for the assessment of patients with suspected Acute Myocardial Infarction (AMI)1

Don’t miss the highly anticipated industry workshop

Cardiac troponin I POC testing in the Emergency Department: What evidence, what applications, what algorithms, what timing, and what technology?

Sponsored by Polymedco

Wednesday, July 31 | 3:30 – 4:30 PM CT | Exhibit hall theater #1

Presented by Robert H Christenson, PhD, DABCC, FADLM, FACC University of Maryland School of Medicine

Attend the presentation and be a part of troponin history in the making! This presentation will explore how the new era of high-sensitivity cardiac troponin testing at the point of care can improve patient and caregiver satisfaction, save system resources, and add value to laboratory medicine services.


Ready to accelerate urgent cardiac care decisions in your ED?

What are you waiting for?

Enter your name and email address to receive more information about PATHFAST hs-cTnI-II.

Exceed your screening goals with the gold-standard in non-invasive CRC screening, OC-Auto FIT

The world’s #1 automated noninvasive colorectal cancer (CRC) screening solution.2 The only FIT supported by a Tier 1 recommendation and backed by clinically proven results3,4

43.8% increase in patient compliance from 38.9% to 82.7%4

25.5% reduction in CRC cases4

52.4% reduction deaths due to colon cancer4


Learn more about annual CRC screening for average-risk patients ages 45-75

About Polymedco

Polymedco partners with healthcare systems, payors, providers, and reference labs to develop best-in-class screening and early detection programs that can help identify life-threatening diseases earlier. We’re proud to offer a portfolio of products with exceptional performance, robust clinical evidence, and user-friendly design.

Visit us in booth #1742 at ADLM to learn more



  1. Kontos, M, de Lemos, J. et al. 2022 ACC Expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(20):1925-1960. doi:10.1016/j.jacc.2022.08.750
  2. Data on file with Polymedco, Inc.
  3. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. doi:10.1038/ ajg.2017.174
  4.  Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383-1391.e5.